U.S. Justice Department Emergency-Schedules Three Potent Synthetic Opioids
The U.S. Department of Justice has announced the emergency scheduling of three highly potent opioid compounds that officials say present an imminent threat to public safety. The substances—mitragynine pseudoindoxyl (MGPI), MGM-15, and MGM-16—are chemically related to mitragynine and 7-hydroxymitragynine and are associated with opioid-like effects.
The action is intended to address the growing availability of manufactured products containing these powerful compounds before their presence in the consumer market expands further.
Attorney General Todd Blanche said the Justice Department is taking action at an early stage to prevent the substances from becoming a more widespread threat. He noted that the compounds are potent opioids that have been incorporated into consumer products, sometimes marketed under labels that may not clearly communicate their potential risks.
According to the department, the emergency scheduling is intended to strengthen federal authorities' ability to protect communities, particularly young people, from the potential harms associated with opioid exposure, dependence, and misuse.
Three Compounds Added to Schedule I
As part of the action, the Drug Enforcement Administration (DEA) is temporarily placing MGPI, MGM-15, and MGM-16 into Schedule I of the Controlled Substances Act.
Preclinical research indicates that all three compounds act as potent mu-opioid receptor agonists. Because of this activity, officials say they may carry risks similar to those associated with other powerful mu-opioid agonists, including physical dependence and potentially dangerous respiratory depression.
The compounds do not all have the same status in the consumer marketplace.
MGPI and MGM-15 have been identified in manufactured products that are marketed for their opioid effects. MGM-16, meanwhile, has not been confirmed in commercially available consumer products. However, authorities describe it as a highly potent compound that could potentially be introduced as an alternative to related substances.
The DEA's emergency scheduling gives federal authorities additional regulatory and enforcement tools as the market for manufactured opioid products continues to evolve.
What Emergency Scheduling Means
Once the temporary scheduling takes effect, the manufacture, distribution, and possession of the covered substances will be subject to the regulatory requirements and administrative, civil, and criminal penalties applicable to Schedule I controlled substances.
The Justice Department said the action is designed to allow the federal government to respond more quickly to an emerging market involving concentrated and deliberately manufactured opioid compounds.
Officials emphasized that the measure is focused on manufactured and concentrated products, rather than traditional botanical kratom.
This distinction is important because the three compounds are related to substances naturally associated with the kratom plant, but the government is specifically targeting products in which these potent compounds are manufactured, concentrated, fortified, or deliberately added.
Botanical Kratom and MGPI
The Justice Department also addressed questions surrounding mitragynine pseudoindoxyl (MGPI) and its potential presence in botanical kratom.
According to the department, the published scientific literature has not established MGPI as a naturally occurring alkaloid of kratom. At the same time, scientific and analytical uncertainties remain regarding whether extremely small, incidental amounts of MGPI could be detected in certain botanical kratom products as a result of factors such as processing, storage, or laboratory testing conditions.
Because of these unresolved scientific questions, the department said it will exercise enforcement discretion when only incidental trace amounts of MGPI are confirmed in a product that otherwise appears consistent with traditional botanical kratom.
Importantly, the department clarified that this enforcement approach does not constitute a legal exemption. MGPI remains classified as a Schedule I controlled substance under the temporary scheduling order.
The policy is intended to distinguish between incidental trace findings and products that deliberately contain manufactured or concentrated amounts of the compound.
Manufactured and Fortified Products Remain a Target
The enforcement discretion policy does not extend to products containing MGM-15 or MGM-16.
It also does not apply when MGPI has been manufactured, concentrated, fortified, or intentionally added to a product.
This means that manufacturers or distributors cannot rely on the enforcement policy when a product has been deliberately formulated to contain elevated levels of MGPI or other covered synthetic compounds.
The Justice Department's position reflects its focus on products that are intentionally engineered to deliver concentrated opioid effects rather than ordinary botanical kratom products containing only naturally occurring trace constituents.
Broader Federal Response to Emerging Opioids
The emergency scheduling represents part of a broader federal effort to respond to rapidly changing synthetic-drug markets.
Manufacturers and suppliers of novel psychoactive substances can modify chemical structures or introduce new compounds as existing substances become subject to regulation. This can make it challenging for regulators and law enforcement agencies to identify and control emerging substances before they become widespread.
By temporarily placing MGPI, MGM-15, and MGM-16 into Schedule I, federal authorities gain additional tools to restrict their manufacture, distribution, and possession while addressing the potential risks associated with these compounds.
The Justice Department also emphasized that the action does not alter the scheduling status of other substances. It likewise does not restrict or otherwise change the authority of the U.S. Food and Drug Administration (FDA) under federal law.
The distinction between traditional botanical kratom and deliberately manufactured or concentrated opioid products is therefore central to the new policy.
As the market for synthetic and semi-synthetic opioid products continues to develop, federal officials say the emergency scheduling will provide an additional mechanism for addressing substances that may pose significant risks of opioid dependence, misuse, and respiratory depression before they become more broadly established in the consumer market.
Source: Office of Public Affairs - US Department of Justice